Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ProthenaPRTA +1.30%74 Degree of Operating Leverage is -0.18 as of Jun. 2026. GuruFocus rates PRTA with a GF Score™ of 74/100 and a GF Value™ of $12.75 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 859 Biotechnology companies, Prothena ranks better than 57.86% on this metric.
Degree of Operating Leverage (DOL) measures the percentage change in EBIT for a unit change in Revenue.
Prothena's Degree of Operating Leverage for the quarter that ended in Jun. 2026 was -0.18. The higher Degree of Operating Leverage, the higher operating risk the company will take.
The industry rank for Prothena's Degree of Operating Leverage or its related term are showing as below:
PRTA's Degree of Operating Leverage is ranked better than 57.86% of 859
companies
in the Biotechnology industry
Industry Median: -0.01
vs PRTA: -0.18
Prothena (NAS:PRTA) Degree of Operating Leverage Explanation
Degree of Operating Leverage (DOL) is a leverage ratio that measures the sensitivity of a company’s operting income, also referred to as Earnings Before Interest and Taxes (EBIT), to fluctuations in its Revenue. DOL is a method used to quantify a company’s operating risk. This risk is related to the company's structure of variable costs and fixed costs. Since the fixed costs do not allow the company to adjust the operating costs, the operating risk rises with a higher fixed-to-variable costs proportion.
A high Degree of Operating Leverage indicates that the company’s fixed costs exceed its variable costs. By increasing the sales, the company can earn more profits. In addition, the company must be able to maintain relatively high sales to cover all fixed costs.
Be Aware
The use of operating leverage varies across different industries and business sectors, and the application of Degree of Operating Leverage (DOL) should be adjusted accordingly.
Prothena Degree of Operating Leverage Related Terms
Prothena Degree of Operating Leverage Historical Data
* Premium members only.
The historical data trend for Prothena's Degree of Operating Leverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PRTA vs EVMN, EDIT, CCCC: Degree of Operating Leverage Comparison
For the Biotechnology subindustry, Prothena's Degree of Operating Leverage, along with its competitors' market caps and Degree of Operating Leverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Prothena Degree of Operating Leverage vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Prothena's Degree of Operating Leverage distribution charts can be found below:
* The bar in red indicates where Prothena's Degree of Operating Leverage falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** TTM data of EBIT and Revenue was used to calculate Degree of Operating Leverage.
*** Please be aware that the Degree of Operating Leverage calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
What does a Degree of Operating Leverage of -0.18 mean?
Prothena (PRTA) has a Degree of Operating Leverage of -0.18 as of Jun. 2026. Degree of Operating Leverage (DOL) measures the percentage change in EBIT for a unit change in Revenue. View historical data for Prothena and its competitors. According to the industry distribution chart, Prothena ranks #362 out of 859 companies in the Biotechnology industry, placing it in the top 42.1%.
Is Prothena's Degree of Operating Leverage too high?
Prothena's current Degree of Operating Leverage is -0.18. Based on the distribution chart, Prothena ranks #362 out of 859 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Prothena has a GF Score™ of 74/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Prothena's Degree of Operating Leverage compare to EVMN and EDIT?
According to the Biotechnology industry distribution chart, Prothena ranks #362 out of 859 companies for Degree of Operating Leverage. This puts Prothena in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Degree of Operating Leverage for a Biotechnology company?
A good Degree of Operating Leverage depends on the Biotechnology industry context. However, Degree of Operating Leverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Degree of Operating Leverage mean?
A high Degree of Operating Leverage can signal that a stock is expensive relative to its fundamentals. Degree of Operating Leverage (DOL) measures the percentage change in EBIT for a unit change in Revenue. View historical data for Prothena and its competitors. Prothena's current Degree of Operating Leverage is -0.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Prothena stock overvalued right now?
Based on GuruFocus' analysis, Prothena (PRTA) is currently considered Possible Value Trap. The stock's GF Value™ is $12.75, compared to a current price of $8.58 — trading 32.7% below its estimated fair value. The current Degree of Operating Leverage is -0.18. Prothena's overall GF Score™ is 74/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Degree of Operating Leverage calculated?
Degree of Operating Leverage is calculated from a company's financial statements. For Prothena (PRTA), the current Degree of Operating Leverage is -0.18 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Prothena (PRTA) Overvalued in 2026?
Based on GuruFocus' analysis, Prothena stock appears to be undervalued.
The current stock price of $8.58 is trading 32.7% below its estimated GF Value™ of $12.75.
GuruFocus considers Prothena to be Possible Value Trap.
Key valuation signals for PRTA:
Degree of Operating Leverage: -0.18
GF Value™: $12.75 vs. price of $8.58 (32.7% below fair value)
No single metric tells the full story. See the PRTA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Prothena Corp PLC is a late-stage clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. Prothena is developing and applying its proprietary CYTOPE technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. The company's pipeline includes both wholly-owned and partnered programs like Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), PRX019, TDP-43 CYTOPE, and PRX012-TfR, being developed for the potential treatment of Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases.
74GF Score
Get the complete analysis for PRTA
Degree of Operating Leverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PRTA has been successfully added to your 
